Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Unknown1
Active Not Recruiting1
Not Yet Recruiting1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT04460937Phase 1Active Not Recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

NCT07469241Phase 2Not Yet Recruiting

Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

NCT06265285Phase 2Recruiting

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

NCT05522894Phase 2UnknownPrimary

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

Showing all 4 trials

Research Network

Activity Timeline